TP53 and non-small cell lung carcinoma: Overall, the majority of recent studies have shown that TP53 mutations are associated with poorer OS in NSCLC patients and support the hypothesis that TP53 (and perhaps other tumor suppressor genes) may affect the efficacy of traditional targeted therapy in molecularly-addicted NSCLC patients by triggering cell proliferation and passing the oncogenic power of the EGFR pathway [27,28,29].